BioCryst Pharmaceuticals | BCRX - الأصول





الأصول تغيير تاريخ
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
BioCryst Pharmaceuticals USD 514.16M 67.73M 2025-12
Chugai Pharma JPY 2.27T 203.49B 2026-03
Daiichi Sankyo JPY 3.82T 252.52B 2025-12
DBV Technologies USD 233.72M 123.22M 2025-12
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novavax USD 1.18B 3.38M 2025-12
PTC Therapeutics USD 2.9B 255.07M 2025-12
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03